

10/599,824

DOCKET NO.: 133087.14701 (101431-1P US)

PATENT

## In the Specification:

BSA 1-26-08

Please amend the table beginning at page 12, line <sup>10</sup>~~13~~ of the International PCT publication as follows:

--Examples ~~2-29~~ 2-28:

The compounds shown in the following table were prepared in a manner analogous to that described in Example 1:

Ex. No.		Name	MW	MS m/z (M+H)+
<u>2</u> <u>1</u>		<del>4-([2-(3,4-dichlorophenyl)-2-piperazin-1-ylethoxy]methyl)-3-methoxy-2-naphthonitrile</del>  <u>4-([2-(3-Chloro-4-fluorophenyl)-2-piperazin-1-ylethoxy]methyl)-3-methoxy-2-naphthonitrile</u>	<del>470.40</del>	<del>470.2, 472.2</del>  <u>454.4</u>
<u>3</u> <u>2</u>		<del>3-methoxy-4-([2-piperazin-1-yl]-2-[3-(trifluoromethoxy)phenyl]ethoxy)methyl)-2-naphthonitrile</del>  <u>4-([2-(3,4-dichlorophenyl)-2-piperazin-1-ylethoxy]methyl)-3-methoxy-2-naphthonitrile</u>	<del>485.51</del>  <u>470.40</u>	<del>486.4</del>  <u>470.2, 472.2</u>
<u>4</u> <u>3</u>		<del>3-methoxy-4-([2-piperazin-1-yl]-2-[3-(trifluoromethoxy)phenyl]ethoxy)methyl)-2-naphthonitrile</del>  <u>3-methoxy-4-([2-piperazin-1-yl]-2-[3-(trifluoromethoxy)phenyl]ethoxy)methyl)-2-naphthonitrile</u>	<del>469.51</del>  <u>485.51</u>	<del>470.5</del>  <u>486.4</u>